Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–Repare Therapeutics, a precision oncology company pioneering synthetic
lethality to develop novel therapeutics that target specific
vulnerabilities of tumors in genetically defined patient populations,
announced today that it has made three key additions to its leadership
team and Board of Directors. Maria Koehler, MD, PhD, is joining May 1^st
as Executive Vice President and Chief Medical Officer and will lead
Repare’s transition to a clinical-stage company. Katina Dorton has
joined as Executive Vice President and Chief Financial Officer and will
lead financial, capital markets and administrative operations. Carol
Schafer has been appointed to the Board of Directors as an independent
director.

“We are pleased to make these important additions to our executive and
governance leadership as Repare embarks on a clinically-driven path to
bring important new cancer medicines to the patients who need them,”
said Lloyd M. Segal, President and Chief Executive Officer of Repare
Therapeutics. Dr. Koehler and Ms. Dorton will be based in Repare’s
offices in Cambridge, MA.

Maria Koehler

Dr. Koehler is a hematologist/oncologist with 20 years in pharmaceutical
and biotechnology companies. She has experience in both early drug
development and bringing new drugs to global markets, having developed
strategies for all stages of cancer drug development and medical
affairs. Prior to joining Repare, Dr. Koehler was Chief Medical Officer
at Bicycle Therapeutics. Prior to Bicycle she was VP, Strategy and
Innovation for Pfizer Oncology, spearheading major acquisitions and
strategic oncology portfolio decisions. Dr. Koehler also served as
Oncology Integrated Development Leader at Pfizer, where she led the
clinical development of Pfizer’s first-in-class breast cancer medicine,
Ibrance® (palbociclib), first approved in 2015 and with sales of more
than $4 billion in 2018.

Dr. Koehler received her MD and PhD from the Silesian Medical School in
Poland and has co-authored over 150 publications, book chapters and
patents.

Katina Dorton

Prior to joining Repare, Ms. Dorton was Chief Financial Officer of
Avrobio (Nasdaq: AVRO), a clinical-stage gene therapy company. At Avro,
Katina led the raise of $175M in equity capital, including the Company’s
$114M IPO. Prior to Avro, Katina was Chief Financial Officer of Immatics
Biotechnologies, a T-cell-based immuno-oncology company. Katina has more
than 15 years of investment banking experience advising corporate
clients and their boards on capital markets, fund raising, mergers and
acquisitions, and other strategic transactions. She was a Managing
Director at Morgan Stanley and a Managing Director at Needham & Co. She
practiced law as an M&A and securities law attorney at Sullivan &
Cromwell prior to her investment banking career. Katina currently serves
as Lead Director at US Ecology (Nasdaq: ECOL), an environmental services
company.

Katina holds a J.D. from the University of Virginia School of Law, an
M.B.A. from George Washington University, and a B.A. from Duke
University.

Carol Schafer

Ms. Schafer is a seasoned financial professional with more than 25 years
of experience in investment banking, equity capital markets, corporate
finance and business development. She most recently served as Vice
Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells
Fargo, Ms. Schafer served as Vice President of Finance and Business
Development at Lexicon Pharmaceuticals. Earlier in her career, she was a
Managing Director and equity capital markets sector head at J.P. Morgan.
She currently sits on the Board of Directors of Idera Pharmaceuticals,
Inc. (Nasdaq: IDRA). Ms. Schafer received a B.A. from Boston College and
an M.B.A from New York University.

About Repare Therapeutics

Repare Therapeutics is pioneering synthetic lethality to develop novel
therapeutics that target specific vulnerabilities of tumors in
genetically defined patient populations. The company’s initial focus is
on novel targeted therapies in cancer types harboring defective
DNA-damage response (DDR)- or genome instability-related functions.
Repare’s SNIPRx™ platform combines a proprietary, high throughput,
CRISPR‐enabled gene editing target discovery technology with
high‐resolution protein crystallography, computational biology,
medicinal chemistry and clinical informatics to rapidly generate small
molecules for clinical investigation. The company is backed by leading
global healthcare investors including Versant Ventures and MPM Capital.
For additional information, please visit www.reparerx.com.

Contacts

Natalie Laurence
Repare Therapeutics Inc.
+1-514-286-4784
[email protected]